Carbonic anhydrase inhibitors developed through 'click tailing'

Current Pharmaceutical Design

Volumn 16, Issue 29, 2010, Pages 3277-3287

  Lopez, Marie ^a   Salmon, Adam J ^a   Supuran, Claudiu T ^b   Poulsen, Sally Ann ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

CA IX; Carbonic anhydrase; Click chemistry; Glycoconjugates; Hypoxia; Medicinal chemistry; Metallocene; Sulfonamide

Indexed keywords

ACETAZOLAMIDE; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE INHIBITOR; DICLOFENAMIDE; ETHOXZOLAMIDE; FLUORINE 18; GLYCOCONJUGATE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; TOPIRAMATE; TRIAZOLE DERIVATIVE; ZONISAMIDE;

ADDITION REACTION; BIOLOGICAL ACTIVITY; CELL HYPOXIA; COMPETITIVE INHIBITION; CYCLOADDITION; DEPROTECTION REACTION; DRUG ACTIVITY; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENVIRONMENTAL TEMPERATURE; HUMAN; HYDROGEN BOND; LIPOGENESIS; LIPOPHILICITY; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NONHUMAN; PHARMACOPHORE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIDE EFFECT; TUMOR CELL; WEIGHT REDUCTION;

CARBONIC ANHYDRASE INHIBITORS; CHEMISTRY, PHARMACEUTICAL; CLICK CHEMISTRY; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; ISOENZYMES; MITOCHONDRIA; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 78649864606     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793429869     Document Type: Review

References (58)

1. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7(2): 168-81.
2. Krishnamurthy VM, Kaufman GK, Urbach AR, et al. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev 2008; 108(3): 946-1051.
3. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60(24): 7075-83.
4. Kaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta - Rev Cancer 2009; 1795(2): 162-72.
5. Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT. Carbonic anhydrase inhibitors. synthesis of watersoluble, topically effective, intraocular pressure-lowering aromatic/ heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem 1999; 42(14): 2641-50.
6. Supuran C, Casini A, Scozzafava A. Development of sulfonamide carbonic anhydrase inhibitors. In: Supuran CT, Scozzafava A, Conway J, Eds. Carbonic anhydrase: Its inhibitors and activators. Florida: CRC Press LLC 2004.
7. Winum JY, Poulsen S-A, Supuran C. Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev 2009; 29: 419-35.
8. Huisgen R, Szeimies G, Moebius L. 1,3-Dipolar cycloadditions XXXII. Kinetics of the addition of organic azides to carbon-carbon multiple bonds. Chem Ber 1967 1967; 100: 2494-507.
9. Tornoe CW, Christensen C, Meldal M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3- dipolar cycloadditions of terminal alkynes to azides. J Org Chem 2002; 67(9): 3057-64.
10. Rostovtsev V, Green LG, Fokin V, Sharpless K. A stepwise huisgen cycloaddition process: Copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem Int Ed 2002; 41: 2596-9.
11. Kolb HC, Finn M, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed 2001; 40(11): 2004-21.
12. Moses JE, Moorhouse AD. The growing applications of click chemistry. Chem Soc Rev 2007; 36(8): 1249-62.
13. Tron GC, Pirali T, Billington RA, Canonico PL, Sorba G, Genazzani AA. Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes. Med Res Rev 2008; 28(2): 278-308.
14. Zhang L, Chen X, Xue P, et al. Ruthenium-catalyzed cycloaddition of alkynes and organic azides. J Am Chem Soc 2005; 127(46): 15998-9.
15. Majireck MM, Weinreb SM. A study of the scope and regioselectivity of the ruthenium-catalyzed [3 + 2]-cycloaddition of azides with internal alkynes. J Org Chem 2006; 71(22): 8680-3.
16. Patani GA, LaVoie EJ. Bioisosterism: a rational approach in drug design. Chem Rev 1996; 96(8): 3147-76.
17. Tron G, Pirali T, Billington R, Canonico P, Sorba G, Genazzani A. Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes. Med Res Rev 2008; 28(2): 278-308.
18. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Disc Today 2003; 8(24): 1128-37.
19. Bourne Y, Kolb H, Radic Z, Sharpless K, Taylor P, Marchot P. Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation. Proc Natl Acad Sci USA 2004; 101: 1449-54.
20. Chiche J, Ilc K, Laferriere J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009; 69(1): 358-68.
21. Swietach P, Vaughan-Jones R, Harris A. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007; 26(2): 299-310.
22. Martinez-Zaguilan R, Seftor E, Seftor R, Chu Y, Gillies R, Hendrix M. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996; 14: 176-86.
23. Brahimi-Horn MC, Pouyssegur J. HIF at a glance. J Cell Sci 2009; 122(8): 1055-7.
24. Potter CPS, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003; 89(1): 2-7.
25. Thiry A, Dogné JM, Masereel B, Supuran CT. Targeting tumorassociated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006; 27(11): 566-73.
26. Wilkinson BL, Bornaghi LF, Houston TA, Innocenti A, Supuran CT, Poulsen SA. A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by click-tailing. J Med Chem 2006; 49(22): 6539-48.
27. Wilkinson BL, Bornaghi LF, Houston TA, et al. Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazolelinked O-glycosides of benzene sulfonamides. J Med Chem 2007; 50(7): 1651-7.
28. Wilkinson BL, Bornaghi LF, Houston TA, et al. Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg Med Chem Lett 2007; 17(4): 987-92.
29. Wilkinson BL, Innocenti A, Vullo D, Supuran CT, Poulsen S-A. Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J Med Chem 2008; 51(6): 1945-53.
30. Lopez M, Drillaud N, Bornaghi LF, Poulsen S-A. Synthesis of SGlycosyl Primary Sulfonamides. J Org Chem 2009; 74(7): 2811-6.
31. Lopez M, Paul B, Hofmann A, et al. S-glycosyl primary sulfonamides - A new structural class for selective inhibition of cancerassociated carbonic anhydrases. J Med Chem 2009; 52(20): 6421-32.
32. Singer M, Lopez M, Bornaghi LF, et al. Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties. Bioorg Med Chem Lett 2009; 19(8): 2273-6.
33. Lopez M, Bornaghi LF, Innocenti A, et al. Sulfonamide linked neoglycoconjugates - A new class of inhibitors for cancerassociated carbonic anhydrases. J Med Chem 2010; 53(7): 2913-26.
34. Kerns EH, Di L. Permeability methods. In: Kerns EH, Di L, Eds. Drug-like properties: concepts, structure design and methods: from adme to toxicity optimization. London: Academic Press 2008: 287-98.
35. Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2003; 13(6): 1005-9.
36. Vullo D, Innocenti A, Nishimori I, et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides- a new target for the design of antitumor and antiglaucoma drugs? Bioorg Med Chem Lett 2005; 15(4): 963-9.
37. Wilkinson BL, Bornaghi LF, Poulsen S-A, Houston TA. Synthetic utility of glycosyl triazoles in carbohydrate chemistry. Tetrahedron 2006; 62(34): 8115-25.
38. Kerns EH, Di L. Lipophilicity methods. In: Kerns EH, Di L, Eds. Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization. London: Academic Press 2008; 260-4.
39. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998; 41: 1007-10.
40. Zhu C, Jiang L, Chen TM, Hwang KK. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 2002; 37: 399-407.
41. [41] FDA guidance for industry. "Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system" 2000.
42. Borras J, Alzuet G, Ferrer S, Supuran CT. Metal complexes of heterocyclic sulfonamides as carbonic anhydrase inhibitors. In: Supuran CT, Scozzafava A, Conway J, Eds. Carbonic anhydrase: its inhibitors and activators. Florida: CRC Press 2004; pp. 183-208.
43. Braun C, Towle J. N1-Silver1 derivatives of sulfanilamide and some related compounds. J Am Chem Soc 1941; 63(12): 3523-.
44. Dyson P, Sava G. Metal-based antitumour drugs in the post genomic era. Dalton Trans 2006: 1929-33.
45. Van Staveren D, Metzler-Nolte N. Bioorganometallic chemistry of ferrocene. Chem Rev 2004; 104(12): 5931-85.
46. Biot C, Glorian G, Maciejewski LA, Brocard JS. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocenechloroquine analogue. J Med Chem 1997; 40: 3715-8.
47. Top S, Tang J, Vessières A, Carrez D, Provot C, Jaouen G. Ferrocenyl hydroxytamoxifen: a prototype for a new range of oestradiol receptor site-directed cytotoxics. Chem Commun 1996: 955-6.
48. Salmon AJ, Williams ML, Innocenti A, Vullo D, Supuran CT, Poulsen SA. Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety. Bioorg Med Chem Lett 2007; 17(18): 5032-5.
49. Siemens Medical Solutions USA Inc, inventor. The development of molecular imaging probes for carbonic anhydrase-IX using click chemistry. WO 2008/124703, 2008.
50. Conroy CW, Schwam H, Maren TH. The nonenzymatic displacement of the sulfamoyl group from different classes of aromatic compounds by glutathione and cysteine. Drug Metabol Dispos 1984; 12(5): 614-8.
51. Poulsen S-A, Vu H. In-situ fragment-based medicinal chemistry: screening by mass spectrometry. In: Zartler ER, Shapiro MJ, Eds. Fragment-based drug discovery a practical approach. Chichester: John Wiley & sons, Ltd 2008; pp. 159-98.
52. Lewis WG, Green LG, Grynszpan F, et al. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed 2002; 41(6): 1053-7.
53. Mocharla VP, Colasson B, Lee LV, et al. In situ click chemistry: enzyme-generated inhibitors of carbonic anhydrase II. Angew Chem Int Ed 2005; 44(1): 116-20.
54. Sharpless KB, Manetsch R. In situ click chemistry: a powerful means for lead discovery. Expert Opin Drug Discov 2006; 1(6): 525-38.
55. Wang J, Sui G, Mocharla VP, et al. Integrated microfluidics for parallel screening of an in situ click chemistry library. Angew Chem Int Ed 2006; 45(32): 5276-81.
56. Supuran CT. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des 2008; 14(7): 641-648.
57. Supuran CT. Carbonic anhydrases--an overview. Curr Pharm Des 2008; 14(7): 603-614.
58. Winum JY, Scozzafava A, Montero JL, Supuran CT. Design of zinc binding functions for carbonic anhydrase inhibitors. Curr Pharm Des 2008; 14(7): 615-621.